Literature DB >> 12032889

Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli.

Anthony D Harris1, Matthew H Samore, Marc Lipsitch, Keith S Kaye, Eli Perencevich, Yehuda Carmeli.   

Abstract

We aimed to illustrate the importance of control-group selection on the results of risk factor analysis for (1) imipenem-resistant Pseudomonas aeruginosa, (2) vancomycin-resistant enterococci (VRE), and (3) ampicillin-sulbactam-resistant Escherichia coli. Case patients were compared with 2 different control groups: patients with the susceptible form of the organism (type 1), and control patients among whom the case patients arose during the same period as the case patients (type 2). Comparison of case patients who had imipenem-resistant P. aeruginosa with type-1 control patients identified use of imipenem (odds ratio [OR], 27.1) and quinolones (OR, 3.25) as a risk factor for selection of antimicrobial resistance, and comparison of the same case patients with type-2 control patients identified imipenem (OR, 6.34). When case patients with VRE were compared with type-1 and with type-2 control patients, use of vancomycin was identified as a risk factor (OR, 4.38 and 2.77, respectively). Comparison of case patients who had ampicillin-sulbactam-resistant E. coli compared with type-1 control patients identified ampicillin-sulbactam (OR, 2.71) and quinolones (OR, 2.72), and comparison with type-2 control patients identified ampicillin-sulbactam (OR, 1.68). The selection of control patients from the potentially suboptimal control type 1 can falsely identify certain antibiotics and overestimate the OR of the resistance-defining antibiotic.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12032889     DOI: 10.1086/340533

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  38 in total

1.  Epidemiology and risk factors of community onset infections caused by extended-spectrum β-lactamase-producing Escherichia coli strains.

Authors:  Cheol-In Kang; Yu Mi Wi; Mi Young Lee; Kwan Soo Ko; Doo Ryeon Chung; Kyong Ran Peck; Nam Yong Lee; Jae-Hoon Song
Journal:  J Clin Microbiol       Date:  2011-12-07       Impact factor: 5.948

2.  Negative controls: a tool for detecting confounding and bias in observational studies.

Authors:  Marc Lipsitch; Eric Tchetgen Tchetgen; Ted Cohen
Journal:  Epidemiology       Date:  2010-05       Impact factor: 4.822

3.  Risk factors for isolation of strains susceptible only to polymyxin among patients with Pseudomonas aeruginosa bacteremia.

Authors:  Matthew E Falagas; Patra K Koletsi; Petros Kopterides; Argyris Michalopoulos
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

4.  Risk factors for multidrug-resistant Pseudomonas aeruginosa acquisition. Impact of antibiotic use in a double case-control study.

Authors:  M Montero; M Sala; M Riu; F Belvis; M Salvado; S Grau; J P Horcajada; F Alvarez-Lerma; R Terradas; M Orozco-Levi; X Castells; H Knobel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-12-24       Impact factor: 3.267

5.  Risk factors associated with linezolid-nonsusceptible enterococcal infections.

Authors:  Jessina C McGregor; Daniel M Hartung; George P Allen; Randy A Taplitz; Robin Traver; Tony Tong; David T Bearden
Journal:  Am J Infect Control       Date:  2012-02-22       Impact factor: 2.918

Review 6.  Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance.

Authors:  Vered Schechner; Elizabeth Temkin; Stephan Harbarth; Yehuda Carmeli; Mitchell J Schwaber
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

Review 7.  Methods and issues in studies of CRE.

Authors:  Scott R Evans; Anthony D Harris
Journal:  Virulence       Date:  2016-07-28       Impact factor: 5.882

8.  Response to emerging infection leading to outbreak of linezolid-resistant enterococci.

Authors:  Marion A Kainer; Rose A Devasia; Timothy F Jones; Bryan P Simmons; Kelley Melton; Susan Chow; Joyce Broyles; Kelly L Moore; Allen S Craig; William Schaffner
Journal:  Emerg Infect Dis       Date:  2007-07       Impact factor: 6.883

9.  Previous Antibiotic Exposure Increases Risk of Infection with Extended-Spectrum-β-Lactamase- and AmpC-Producing Escherichia coli and Klebsiella pneumoniae in Pediatric Patients.

Authors:  Danielle M Zerr; Arianna Miles-Jay; Matthew P Kronman; Chuan Zhou; Amanda L Adler; Wren Haaland; Scott J Weissman; Alexis Elward; Jason G Newland; Theoklis Zaoutis; Xuan Qin
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

10.  Incidence and risk factors for nosocomial infections caused by fluoroquinolone-resistant Escherichia coli.

Authors:  K Huotari; E Tarkka; V Valtonen; E Kolho
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-07-18       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.